VEGFA and spondylo-ocular syndrome: VEGF was found to be elevated in liver tissue and plasma of patients with SOS [11,12], which may provide a good hypothesis that the addition of bevacizumab (an inhibitor of vascular endothelial growth factor, VEGF) to oxaliplatin-based neoadjuvant regimens is associated with protective effects against the development of SOS [13].